MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- IPCA LABS - ADCOCK INGRAM (S. Africa)
IPCA LABS vs ADCOCK INGRAM (S. Africa) - Comparison Results
IPCA LABS Change
Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More
ADCOCK INGRAM (S. Africa)
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
Financials
 IPCA LABS  ADCOCK INGRAM |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| IPCA LABS Mar-19 |
ADCOCK INGRAM Jun-14 |
IPCA LABS/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,042 | 317 | - | |
| Low | Rs | 590 | 229 | - | |
| Sales per share (Unadj.) | Rs | 298.6 | 94.2 | - | |
| Earnings per share (Unadj.) | Rs | 35.0 | -23.7 | - | |
| Cash flow per share (Unadj.) | Rs | 49.4 | -19.7 | - | |
| Dividends per share (Unadj.) | Rs | 3.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.4 | 0 | - | |
| Book value per share (Unadj.) | Rs | 247.1 | 74.0 | - | |
| Shares outstanding (eoy) | m | 126.35 | 168.78 | - | |
| Bonus/Rights/Conversions | ESOS | - | - | ||
| Price / Sales ratio | x | 2.7 | 2.9 | 94.4% | |
| Avg P/E ratio | x | 23.3 | -11.5 | -203.1% | |
| P/CF ratio (eoy) | x | 16.5 | -13.9 | -119.1% | |
| Price / Book Value ratio | x | 3.3 | 3.7 | 89.6% | |
| Dividend payout | % | 8.6 | 0 | - | |
| Avg Mkt Cap | Rs m | 103,108 | 46,024 | 224.0% | |
| No. of employees | `000 | 13.4 | 4.3 | 313.1% | |
| Total wages/salary | Rs m | 7,874 | 2,889 | 272.6% | |
| Avg. sales/employee | Rs Th | 2,807.0 | 3,705.3 | 75.8% | |
| Avg. wages/employee | Rs Th | 585.8 | 672.9 | 87.1% | |
| Avg. net profit/employee | Rs Th | 329.0 | -933.7 | -35.2% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 37,732 | 15,907 | 237.2% | |
| Other income | Rs m | 577 | 111 | 517.8% | |
| Total revenues | Rs m | 38,309 | 16,018 | 239.2% | |
| Gross profit | Rs m | 6,901 | -2,757 | -250.3% | |
| Depreciation | Rs m | 1,824 | 687 | 265.7% | |
| Interest | Rs m | 189 | 431 | 43.8% | |
| Profit before tax | Rs m | 5,465 | -3,763 | -145.2% | |
| Minority Interest | Rs m | 0 | -10 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 1,042 | 235 | 443.4% | |
| Profit after tax | Rs m | 4,422 | -4,008 | -110.3% | |
| Gross profit margin | % | 18.3 | -17.3 | -105.5% | |
| Effective tax rate | % | 19.1 | -6.2 | -305.3% | |
| Net profit margin | % | 11.7 | -25.2 | -46.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 23,778 | 11,650 | 204.1% | |
| Current liabilities | Rs m | 10,975 | 6,555 | 167.4% | |
| Net working cap to sales | % | 33.9 | 32.0 | 105.9% | |
| Current ratio | x | 2.2 | 1.8 | 121.9% | |
| Inventory Days | Days | 104 | 111 | 93.5% | |
| Debtors Days | Days | 66 | 124 | 53.2% | |
| Net fixed assets | Rs m | 20,368 | 6,791 | 299.9% | |
| Share capital | Rs m | 253 | 74 | 342.2% | |
| Net worth | Rs m | 31,224 | 12,485 | 250.1% | |
| Long term debt | Rs m | 1,409 | 4,387 | 32.1% | |
| Total assets | Rs m | 45,507 | 23,585 | 192.9% | |
| Interest coverage | x | 30.0 | -7.7 | -387.5% | |
| Debt to equity ratio | x | 0 | 0.4 | 12.8% | |
| Sales to assets ratio | x | 0.8 | 0.7 | 122.9% | |
| Return on assets | % | 10.1 | -15.2 | -66.8% | |
| Return on equity | % | 14.2 | -32.1 | -44.1% | |
| Return on capital | % | 17.3 | -19.8 | -87.5% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 4,923 | 1,358 | 362.6% | |
| From Investments | Rs m | -1,563 | -417 | 374.9% | |
| From Financial Activity | Rs m | -1,832 | 3,982 | -46.0% | |
| Net Cashflow | Rs m | 1,528 | 4,923 | 31.0% | |
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.37 Rs / ZAR
Compare IPCA LABS With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare IPCA LABS With: TTK HEALTHCARE PFIZER JUBILANT LIFE SCIENCES STERLING BIOTECH AJANTA PHARMA
Today's Market
Indian Indices Continue Momentum; Sensex Ends 284 Points Higher(Closing)
Indian share markets witnessed positive trading activity throughout the day today and ended on a strong note.
Related Views On News
IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)
Feb 17, 2020 | Updated on Feb 17, 2020For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)
Nov 12, 2019 | Updated on Nov 12, 2019For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
More Views on NewsMost Popular
6 Charts Showing the State of Indian Financial Markets in 2020 (Sector Info)
May 26, 2020Six charts showing how Indian financial markets have performed in 2020 so far...
Why We Picked This Smallcap Stock for a Post Coronavirus World (Profit Hunter)
May 28, 2020Covid-19 has made it a survival of the fittest race for many companies. The ones that can adapt will thrive in a post crisis world.
Which Stocks Should You Buy, Sell, and Hold in the Market Today? (Profit Hunter)
May 21, 2020The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...
What the RBI's Rate Cut Means for Options Traders (Fast Profits Daily)
May 25, 2020The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.
More